109 related articles for article (PubMed ID: 31319387)
21. PTCH1 gene mutations in exon 17 and loss of heterozygosity on D9S180 microsatellite in sporadic and inherited human basal cell carcinomas.
Santos DC; Zaphiropoulos PG; Neto CF; Pimentel ER; Sanches JA; Ruiz IR
Int J Dermatol; 2011 Jul; 50(7):838-43. PubMed ID: 21699520
[TBL] [Abstract][Full Text] [Related]
22. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.
Mohan SV; Chang J; Li S; Henry AS; Wood DJ; Chang AL
JAMA Dermatol; 2016 May; 152(5):527-32. PubMed ID: 26914338
[TBL] [Abstract][Full Text] [Related]
23. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
25. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
26. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.
Winkler JK; Schneiderbauer R; Bender C; Sedlaczek O; Fröhling S; Penzel R; Enk A; Hassel JC
Br J Dermatol; 2017 Feb; 176(2):498-502. PubMed ID: 27061826
[No Abstract] [Full Text] [Related]
27. A novel PTCH1 gene mutation in a pediatric patient associated multiple keratocystic odontogenic tumors of the jaws and Gorlin-Goltz syndrome.
Ozcan G; Balta B; Sekerci AE; Etoz OA; Martinuzzi C; Kara O; Pastorino L; Kocoglu F; Ulker O; Erdogan M
Indian J Pathol Microbiol; 2016; 59(3):335-8. PubMed ID: 27510672
[TBL] [Abstract][Full Text] [Related]
28. Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome.
Moreira A; Kirchberger MC; Toussaint F; Erdmann M; Schuler G; Heinzerling L
Br J Dermatol; 2018 Sep; 179(3):747-749. PubMed ID: 29603722
[TBL] [Abstract][Full Text] [Related]
29. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
30. Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.
Sindhu S; Gimber LH; Cranmer L; McBride A; Kraft AS
J Immunother Cancer; 2017 Jul; 5(1):58. PubMed ID: 28716069
[TBL] [Abstract][Full Text] [Related]
31. Mitochondrial D310 D-Loop instability and histological subtypes in radiation-induced cutaneous basal cell carcinomas.
Boaventura P; Pereira D; Mendes A; Batista R; da Silva AF; Guimarães I; Honavar M; Teixeira-Gomes J; Lopes JM; Máximo V; Soares P
J Dermatol Sci; 2014 Jan; 73(1):31-9. PubMed ID: 24091058
[TBL] [Abstract][Full Text] [Related]
32. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
33. Comparison of PTCH1, COX-2, p53, and Ki-67 protein expression in basal cell carcinomas of nodular and superficial subtypes arising on the head and trunk.
Khalesi M; Waterhouse M; Whiteman DC; Johns R; Rosendahl C; Hackett T; Pollak T; Kimlin MG; Hacker E; Neale RE;
Int J Dermatol; 2016 Oct; 55(10):1096-105. PubMed ID: 27126210
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities.
Spallone G; Sollena P; Ventura A; Fargnoli MC; Gutierrez C; Piccerillo A; Tambone S; Bianchi L; Peris K
Dermatol Ther; 2019 Nov; 32(6):e13108. PubMed ID: 31606940
[TBL] [Abstract][Full Text] [Related]
35. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
36. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
[TBL] [Abstract][Full Text] [Related]
37. Patient with Gorlin syndrome and metastatic basal cell carcinoma refractory to smoothened inhibitors.
Zhu GA; Li AS; Chang AL
JAMA Dermatol; 2014 Aug; 150(8):877-9. PubMed ID: 24898076
[TBL] [Abstract][Full Text] [Related]
38. Metastatic basal cell carcinoma: report of a case presenting with respiratory failure.
Degner RA; Kerley SW; McGregor DH; Dixon AY
Am J Med Sci; 1991 Jun; 301(6):395-7. PubMed ID: 2039026
[TBL] [Abstract][Full Text] [Related]
39. Understanding the Molecular Genetics of Basal Cell Carcinoma.
Pellegrini C; Maturo MG; Di Nardo L; Ciciarelli V; Gutiérrez García-Rodrigo C; Fargnoli MC
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165358
[TBL] [Abstract][Full Text] [Related]
40. Familial seborrhoeic keratosis associated with multiple 'pure reticulated acanthomas' and infundibulocystic basal cell carcinomas.
Agustí Martínez J; Bella-Navarro R; García-García AB; Bueno E; González-Sarmiento R; Navarro L; Sanchez-Sendra B; Revert A; Jordá E; Monteagudo C
Br J Dermatol; 2017 Dec; 177(6):1654-1663. PubMed ID: 28627087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
